"We added research-based biopharmaceutical company, AbbVie Inc. (NYSE:ABBV) following a recent pullback in shares related to a Phase 2 clinical failure for schizophrenia drug, Emraclidine. Despite the setback, we believe AbbVie's core inflammation and immunology (I&I) business is set to outperform. We expect next-generation I&I drugs, Skyrizi and Rinvoq, used in the treatment of inflammatory bowel disease, to be key long-term revenue drivers."